Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis

•Patients with thoracic cancers and COVID-19 have high mortality and morbidity.•Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited.•We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927)...

Full description

Saved in:
Bibliographic Details
Published inClinical lung cancer Vol. 25; no. 5; pp. e229 - e237.e7
Main Authors Kulkarni, Amit A., Hennessy, Cassandra, Wilson, Grace, Ramesh, Vidhyalakshmi, Hwang, Clara, Awosika, Joy, Bakouny, Ziad, Khan, Hina, Vilar-Compte, Diana, McKay, Rana, Jani, Chinmay, Weissmann, Lisa, Griffiths, Elizabeth, Batist, Gerald, Bouganim, Nathaniel, Mavromatis, Blanche, Bashir, Babar, Nguyen, Ryan H., Riess, Jonathan W., Puc, Matthew, Kasi, Anup, Berg, Stephanie, Castillo, Dan Ran, Hayes-Lattin, Brandon, Hosmer, Wylie, Flora, Daniel, Mishra, Sanjay, French, Benjamin, Warner, Jeremy L., Lopes, Gilberto, Peters, Solange, Florez, Narjust
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2024
Subjects
Aged
Antineoplastic Agents - therapeutic use
Chemotherapy
COVID-19 - epidemiology
Female
Humans
Immunotherapy
Male
Middle Aged
Registries
SARS-CoV-2
Targeted therapy
Thoracic Cancers
Thoracic Neoplasms - drug therapy
Chemotherapy
Thoracic Cancers
Targeted therapy
Immunotherapy
Online AccessGet full text

Cover

More Information
Summary:•Patients with thoracic cancers and COVID-19 have high mortality and morbidity.•Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited.•We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19).•As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity.•None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality.•Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Authors contributed equally
ISSN:1525-7304
1938-0690
1938-0690
DOI:10.1016/j.cllc.2024.04.003